2026³â 06¿ù 27ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and bet

Evinova¡¯s globally-scaled digital health solutions are evidence-led, science-based and human experience-driven to serve clinical trial sponsors, clinical research organisations (CROs), clinical trial site care teams and patients
´º½ºÀÏÀÚ: 2023-11-22

WILMINGTON, DEL.-- AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.

Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.

Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”

Cristina Duran, President of Evinova, said: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”

Globally-leading CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their wide customer base. To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services.

Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science. In addition to digital solutions, Evinova will offer custom scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as trial design and consulting services.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Audiencerate Appoints Riccardo Fabbri CTO, Launching AI-Driven Phase for SMEs and Media Agencies
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
Twilio Recognized as a Leader in the 2026 Gartner Magic Quadrant for CPaaS for the Fourth Consecutive Year
RebuilderAI Introduces Brand-Exclusive Design-to-Manufacturing AI Agent ¡®VRING:ON¡¯ at VivaTech 2026
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Data, Seamless Connectivity, and Governance
TestMu AI Expands Real Device Testing With Playwright Multi-Language and Advanced iOS Audio Features
FurtherAI Appoints Tom Bradley to Lead UK and EU Expansion

 

Miro Takes Aim at the Gap Between AI Potential and Organizational Real...
BeOne Medicines Launches Global Cancer Care Campaign With Soccer Legen...
Aircall Acquires Piper AI to Turn Customer Conversations Into Revenue ...
Boomi to Acquire Lunar.dev to Deliver Governed Agent Connectivity Acro...
Prokarium Reports Positive Interim PARADIGM-1 Data of ZH9 in NMIBC, Sh...
Training Lasers Installed at Gigaphoton Kyushu Office
LTM Launches BlueVerse¢â for iRun to Outcreate Managed Services in the...

 


°øÁö»çÇ×
¹Ìµð¾î¿Í M• Mediaour ØÚ体ä² ØÚô÷ä² ¿¥¿À MO ØÚä²
¾Ë¸®¾Ë A⋮⋮⋮ Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
À£ÇÁ·Ò W⋮⋮⋮ Welfrom 卫ÜØ êÛÝ£
¹ÙÀÌ¿ÀÀÌ´Ï B⋮ BIOINI ù±药研 ¹ÙÀÌ¿ÀÀÌ´Ï·¦ BIOINILAB ...
º£³×ÀÍ ¡Õ Beneik 宝Ò¬ìÌ, À̺ñÁî eBizh æ¶币òª EZ æ¶òª
¿¡³ÊÀÌÀ¯ ¡Õ¡Õ EnerEU 额Òö äþÒö
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¾Ë¸®À¯ºñ ^v Alliuv ä¹备 AV ä¹êó备, ¾Ë¶ã =^= Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º ¡ÕC À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò ^ Alfrom ä¹尔ÜØ ä¹ì³ÜØ, ¿ÃÇÁ·Ò A⋮⋮ Allfrom &...

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..